Making a difference with your help.
Protocol Name: Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease Protocol #: VX24-147-202 Indication: APOL1-Mediated Proteinuric Kidney Disease GFR: ≥25 to ≤75 Principal Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: Observational Study Protocol – Fabry Disease Registry Protocol #: DIREGC07006 Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Observational Study Protocol – Fabry Disease Registry Read More »
Protocol Name: Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease Protocol #: VX21-147-301 Indication: APOL1-Mediated Proteinuric Kidney Disease Primary Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >